For research use only. Not for therapeutic Use.
MethADP (Adenosine 5′-(α,β-methylene)diphosphate) triammonium is a CD73 inhibitor. MethADP can be used for the research of ATP-adenosine pathway[1].
MethADP (20 and 100 μmol/L) inhibits 5’-AMP induced adenosine formation in A498 cells[1].
| Catalog Number | I041432 |
| Synonyms | [[(2R,3R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid;azane |
| Molecular Formula | C11H26N8O9P2 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H17N5O9P2.3H3N/c12-9-6-10(14-2-13-9)16(3-15-6)11-8(18)7(17)5(25-11)1-24-27(22,23)4-26(19,20)21;;;/h2-3,5,7-8,11,17-18H,1,4H2,(H,22,23)(H2,12,13,14)(H2,19,20,21);3*1H3/t5-,7+,8?,11-;;;/m1.../s1 |
| InChIKey | YVNOVOOCZCMYRN-XFFDLAHRSA-N |
| SMILES | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(CP(=O)(O)O)O)O)O)N.N.N.N |
| Reference | [1]. Mohlin C, et al. Studies of the extracellular ATP-adenosine pathway in human urinary tract epithelial cells. Pharmacology. 2009;84(4):196-202. |
